Klaus G. Parhofer
Research Subjects
Research Interests
Klaus G. Parhofer has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
A. Bhaumik
Bristol‐Myers Squibb, Princeton, NJ, USA
1 shared publicationA. Ptaszynska
Bristol‐Myers Squibb, Princeton, NJ, USA
1 shared publicationK. I. Birkeland
Department of Endocrinology, Aker University Hospital and Faculty of Medicine, University of Oslo, Oslo, Norway
1 shared publicationR. DeFronzo
Diabetes Division, University of Texas Health Science Centre and the Audie L. Murphy Memorial Veterans Affairs Hospital in San Antonio, TX, USA
1 shared publication- Stefano Del Prato
Interdisciplinary Research Center ‘Health Science’, Sant’Anna School of Advanced Studies, Pisa, Italy
1 shared publication
Latest Publications
- 12 November 2018
- Published by Springer Nature in MMW - Fortschritte der Medizin
- Vol. 160 (S3) , 42-44
LDL-Cholesterin: Die klar definierten Zielwerte ernst nehmen!
- 12 November 2018
- Published by Springer Nature in MMW - Fortschritte der Medizin
- Vol. 160 (S3) , 42-44
LDL-Cholesterin: Die klar definierten Zielwerte ernst nehmen!
- Open Access
- 1 May 2012
- Published by Taylor & Francis in Core Evidence
- Vol. 7, 29-38
Mipomersen: evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemia
Peer reviewed article authored by (Parhofer KG). Read article or submit your manuscript for publishing.
- 1 May 2012
- Published by Taylor & Francis in Core Evidence
- Vol. 7, 29-38
Open AccessMipomersen: evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemia
Peer reviewed article authored by (Parhofer KG). Read article or submit your manuscript for publishing.
- 19 November 2009
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 64 (2) , 160-168
Irbesartan has no short-term effect on insulin resistance in hypertensive patients with additional cardiometabolic risk factors (i-RESPOND)
Aims: Intervention studies have shown that angiotensin receptor blockers (ARB) may reduce the incidence of type 2 diabetes mellitus. It is currently unclear whether short-term therapy with ARBs affects metabolic parameters. Methods: i-RESPOND, a randomised, controlled, multicentre, double-blind study evaluated the effect of 16 weeks of irbesartan vs. hydrochlorothiazide (HCTZ) on insulin resistance as well as on lipid and inflammatory parameters in hypertensive subjects with metabolic syndrome. Patients received irbesartan (150 mg/d; n = 211) or HCTZ (12.5 mg/d; n = 215), titrated to 300 mg/day and 25 mg/day respectively. In a second part of the study (weeks 16-28), patients initially randomised to irbesartan received additional HCTZ and vice versa. Results: At week 16 both irbesartan and HCTZ had no effect on insulin resistance measured by the Matzuda index and beta-cell function. Similarly, in the second part of the study (week 16-28) no differences between irbesartan and HCTZ with respect to glucose metabolism were observed. However, irbesartan induced beneficial changes in high-sensitivity-C-reactive protein (hs-CRP) (irbesartan:) -5.5 +/- 5.2%; HCTZ + 19.9 +/- 6.5%, p = 0.0024) and in urinary albumin/creatinine ratio (ACR) (irbesartan:) -13%; HCTZ + 9%; p = 0.0041) compared with HCTZ despite a similar decrease in blood pressure in both treatment groups. Irbesartan and HCTZ were well tolerated and adverse events were comparable. Conclusion: Irbesartan did not show significant favourable effects on insulin resistance compared with HCTZ in this study; however, may have beneficial effects on inflammation and microalbuminuria in hypertensive patients with metabolic syndrome
- 19 November 2009
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 64 (2) , 160-168
Irbesartan has no short-term effect on insulin resistance in hypertensive patients with additional cardiometabolic risk factors (i-RESPOND)
Aims: Intervention studies have shown that angiotensin receptor blockers (ARB) may reduce the incidence of type 2 diabetes mellitus. It is currently unclear whether short-term therapy with ARBs affects metabolic parameters. Methods: i-RESPOND, a randomised, controlled, multicentre, double-blind study evaluated the effect of 16 weeks of irbesartan vs. hydrochlorothiazide (HCTZ) on insulin resistance as well as on lipid and inflammatory parameters in hypertensive subjects with metabolic syndrome. Patients received irbesartan (150 mg/d; n = 211) or HCTZ (12.5 mg/d; n = 215), titrated to 300 mg/day and 25 mg/day respectively. In a second part of the study (weeks 16-28), patients initially randomised to irbesartan received additional HCTZ and vice versa. Results: At week 16 both irbesartan and HCTZ had no effect on insulin resistance measured by the Matzuda index and beta-cell function. Similarly, in the second part of the study (week 16-28) no differences between irbesartan and HCTZ with respect to glucose metabolism were observed. However, irbesartan induced beneficial changes in high-sensitivity-C-reactive protein (hs-CRP) (irbesartan:) -5.5 +/- 5.2%; HCTZ + 19.9 +/- 6.5%, p = 0.0024) and in urinary albumin/creatinine ratio (ACR) (irbesartan:) -13%; HCTZ + 9%; p = 0.0041) compared with HCTZ despite a similar decrease in blood pressure in both treatment groups. Irbesartan and HCTZ were well tolerated and adverse events were comparable. Conclusion: Irbesartan did not show significant favourable effects on insulin resistance compared with HCTZ in this study; however, may have beneficial effects on inflammation and microalbuminuria in hypertensive patients with metabolic syndrome